Literature DB >> 2556080

Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.

K Hoshino1, K Sato, T Une, Y Osada.   

Abstract

The in vitro inhibitory effects of quinolones on the bacterial DNA gyrase of Escherichia coli KL-16 and topoisomerase II of fetal calf thymus were compared. All the quinolones tested required higher concentrations to inhibit the topoisomerase II than to inhibit the DNA gyrase, and no correlation existed among their inhibitory activities against both enzymes. However, there was a large difference among the quinolones in their selectivities between the bacterial enzyme and its eucaryotic counterpart. The selectivity of ofloxacin was highest, and the selectivities of CI-934 and nalidixic acid were lowest.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2556080      PMCID： PMC172762          DOI： 10.1128/AAC.33.10.1816

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  The intrinsic ATPase of DNA gyrase.

Authors:  A Sugino; N R Cozzarelli
Journal:  J Biol Chem       Date:  1980-07-10       Impact factor: 5.157

3.  Influence of two quinolones, ofloxacin and pefloxacin, on human myelopoiesis in vitro.

Authors:  F Pallavicini; A Antinori; G Federico; M Fantoni; P Nervo
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

4.  DNA topoisomerases from rat liver: physiological variations.

Authors:  M Duguet; C Lavenot; F Harper; G Mirambeau; A M De Recondo
Journal:  Nucleic Acids Res       Date:  1983-02-25       Impact factor: 16.971

5.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

6.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

7.  Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings.

Authors:  T Goto; J C Wang
Journal:  J Biol Chem       Date:  1982-05-25       Impact factor: 5.157

8.  DNA topoisomerase II from Drosophila melanogaster. Purification and physical characterization.

Authors:  E R Shelton; N Osheroff; D L Brutlag
Journal:  J Biol Chem       Date:  1983-08-10       Impact factor: 5.157

9.  DNA gyrase: affinity chromatography on novobiocin-Sepharose and catalytic properties.

Authors:  W L Staudenbauer; E Orr
Journal:  Nucleic Acids Res       Date:  1981-08-11       Impact factor: 16.971

10.  Purification and characterization of Xenopus laevis topoisomerase II.

Authors:  P Benedetti; M I Baldi; E Mattoccia; G P Tocchini-Valentini
Journal:  EMBO J       Date:  1983       Impact factor: 11.598
View more
  28 in total

1.  Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans.

Authors:  K Shiba; O Sakai; J Shimada; O Okazaki; H Aoki; H Hakusui
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 2.  Genomics and antimicrobial drug discovery.

Authors:  D T Moir; K J Shaw; R S Hare; G F Vovis
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

3.  Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

Authors:  K Hoshino; K Sato; K Akahane; A Yoshida; I Hayakawa; M Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 4.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

Authors:  D Beauchamp; G Laurent; L Grenier; P Gourde; J Zanen; J A Heuson-Stiennon; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.

Authors:  T Akasaka; S Kurosaka; Y Uchida; M Tanaka; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

7.  A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.

Authors:  A H Corbett; P Guerry; P Pflieger; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 8.  Quinolone mode of action--new aspects.

Authors:  D C Hooper
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Mechanism of differential activities of ofloxacin enantiomers.

Authors:  I Morrissey; K Hoshino; K Sato; A Yoshida; I Hayakawa; M G Bures; L L Shen
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.

Authors:  M Tanaka; K Sato; Y Kimura; I Hayakawa; Y Osada; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.